Trial Profile
A Randomized, Open-Label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Olanzapine (Primary) ; Olanzapine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 02 Jun 2011 Remission results presented at the 10th World Congress of Biological Psychiatry.
- 01 Sep 2010 Results were presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.